ARC-520

Chardan has upgraded Arbutus Biopharma Corp (NASDAQ: ABUS) to Neutral following its underperformance versus Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) and the S&P biotech index. Over the past month, Arbutus shares have dropped 26 percent, in contrast to both Arrowhead shares (+11 percent) and...

Shares of Arrowhead Research Corp (NASDAQ: ARWR) lost more than 50 percent from a year ago. Edward Tenthoff of Piper Jaffray left Arrowhead's R&D day "more confident" that the company's ARC-520 is an active drug for HBV. Tenthoff maintained an Overweight rating with a price target boosted to $...